Citigroup Lowers Bruker (NASDAQ:BRKR) Price Target to $50.00

Bruker (NASDAQ:BRKR) had its price target reduced by stock analysts at Citigroup from $75.00 to $50.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Citigroup’s target price indicates a potential upside of 31.41% from the company’s current price.

A number of other equities research analysts have also recently weighed in on BRKR. Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Barclays cut their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. UBS Group started coverage on Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target on the stock. Stifel Nicolaus dropped their price objective on Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a research note on Friday, February 14th. Finally, Bank of America increased their target price on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Bruker currently has an average rating of “Moderate Buy” and an average target price of $68.00.

Bruker Trading Up 4.4 %

Shares of Bruker stock traded up $1.59 during mid-day trading on Monday, hitting $38.05. The stock had a trading volume of 1,442,442 shares, compared to its average volume of 1,402,902. The firm has a market cap of $5.77 billion, a P/E ratio of 50.28, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The firm has a 50-day moving average of $48.64 and a two-hundred day moving average of $56.00. Bruker has a 12-month low of $34.10 and a 12-month high of $91.34.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Sell-side analysts forecast that Bruker will post 2.69 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC lifted its position in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. raised its stake in Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after buying an additional 248 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in shares of Bruker by 274.9% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company’s stock worth $46,000 after acquiring an additional 800 shares in the last quarter. Quadrant Capital Group LLC boosted its position in shares of Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock worth $75,000 after acquiring an additional 196 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 412 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.